Certolizumab pegol

Category
biologic
Half-Life (t½)
SC: 14d
Aliases
Cimzia, PEGylated anti-TNFα Fab'

Pharmacological Mechanism

Humanised anti-TNFα Fab' fragment conjugated to a 40 kDa branched polyethylene glycol (PEG) moiety. Lacks the IgG Fc region → no complement activation, no antibody-dependent cytotoxicity, and importantly no FcRn-mediated transplacental transfer (preferred anti-TNF during pregnancy). PEGylation extends half-life and reduces immunogenicity compared to native Fab'.

Half-Life & Elimination Curve (SC: 14d)

100%50%25%12.5%0%0h0×t½14d1×t½28d2×t½42d3×t½56d4×t½70d5×t½0×t½ (0h): 100% remaining (~50.8 mg/L)1×t½ (14d): 50% remaining (~25.4 mg/L)2×t½ (28d): 25% remaining (~12.7 mg/L)3×t½ (42d): 12.5% remaining (~6.35 mg/L)4×t½ (56d): 6.3% remaining (~3.17 mg/L)5×t½ (70d): 3.1% remaining (~1.59 mg/L)
Elimination (SC)
  • 0×t½0h100% (50.8 mg/L)
  • 1×t½14d50% (25.4 mg/L)
  • 2×t½28d25% (12.7 mg/L)
  • 3×t½42d12.5% (6.35 mg/L)
  • 4×t½56d6.3% (3.17 mg/L)
  • 5×t½70d3.1% (1.59 mg/L)
Elimination t½14d (SC)
Rate Constant (ke)0.00206 h⁻¹
Est. Peak (Cmax)50.8 mg/L
Clearance (CL)0.013 L/h
97% Washout (5×t½)70d

Dosing Guidelines

Pharmacokinetic Parameters

Pathways It Modulates

Target Organ Systems

References